ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

VOLUME 1 * NUMBER 6 * JUNE 1972 EDITORIAL BOARD

GLADYS L. HOBBY, Editor-in-Chief (1975) Infectious Disease Research Institute, East Orange, N.J. WALTER D. CELMER, Editor (1975) EDWARD W. HOOK, Editor (1976) Pfizer hIc., Grotoln, Coiml. University of Virginia, Charlottesville JOEL G. FLAKS, Editor (1976) LEON H. SCHMIDT, Editor (1974) University ofPennsylvania, Phliladelphia Southern Research Institute, Birminglham, Ala.

Fred Allison, Jr. (1973) H. Grisebach (1974) T. J. Perun (1974) Theodore Anderson (1973) Jack Gwaltney (1974) K. E. Price (1973) Robert Austrian (1974) Fred Hahn (1973) C. Reilly (1972) John Bennett (1973) William Hewitt (1974) R. W. Rickards (1974) Joe Bertino (1974) Richard Hornick (1974) R. W. Riddell (1974) E. Borowski (1973) Milton Huppert (1974) Richard Roberts (1973) D. Buyske (1974) George Gee Jackson (1974) L. Sabath (1973) Yves Chabbert (1974) Keith Jensen (1974) Arthur K. Saz (1973) Patricia Charache (1974) E. H. Kass (1973) F. C. Sciavolino (1973) Ernest Chick (1973) Donald Kaye (1973) Piero Sensi (1974) Leighton E. Cluff (1974) WVm. Kirby (1973) David Smith (1974) Frank Collins (1973) Vernon Knight (1974) Earle Spaulding (1974) John Corcoran (1974) M. Glenn Koenig (1973) Gene Stollerman (1974) Julian Davies (1973) Calvin Kunin (1972) R. Sutherland (1973) Bernard Davis (1973) Mark Lepper (1972) Morton N. Swartz (1973) Arnold L. Demain (1973) Robert G. Loudon (1974) Ralph Tompsett (1973) Roger DesPrez (1973) Thomas H. Maran (1974) John P. Utz (1973) Liebor Ebringer (1974) Lester Mitscher (1974) D. Vazquez (1974) H. L. Ennis (1974) S. Mitsuhashi (1974) G. H. Wagman (1974) Maxwell Finland (1973) R. B. Morin (1973) Kenneth S. W'arren (1973) Harry Gooder (1973) L. Nickell (1974) B. Weisblum (1973) M. Gorman (1974) David Perlman (1972) Temple Williams (1973)

ROBERT A. DAY, Managing Editor, 1913 1 St., N. W., Washingtont, D.C. 20006

EX OFFICIO

MORRIS F. SHAFFER, President (1971-1972) R. G. E. MURRAY, Vice-President (1971-1972) DONALD E. SHAY, Secretary T. J. CARSKI, Treasurer

Antimicrobial Agents and Chemotherapr, a publication of the 20006. Correspondence from ASM members relating to member- American Society for Microbiology, 1913 I St., N.W., Washington, ship dues, member subscriptions, changes of address, incorrect D.C. 20006, is devoted to the dissemination of knowledge relating journaLs, etc, should be directed to the Executive Secretary, to all aspects of antimicrobial agents and chemotherapy, including American Society for Microbiology, 1913 I St., N.W., Washington, cancer chemotherapy. Antimicrobial Agents and Clhemotherapy D.C. 20006. Published monthly by the ASM at 428 E. Preston St.. is published monthly, and the twelve numbers are divided into Baltimore, Md 21202. two volumes per year. The subscription price is $40 (foreign, $41) per year. Single copies are $4.00 (foreign, $4.25). Members of the American Society for Microbiology may receive Antimicrobial Agents and Chemotherapy as part of their dues. Correspondence Application to mail at second-class postage rates is pending at relating to subscriptions, reprints, defective copies, availability of Washington, D.C. back issues, lost or late proofs, disposition of submitted manu- Made in the United States of America. scripts, and general editorial matters should be directed to the Copyright © 1972, American Society for Microbiology ASM Publications Office, 1913 I St., N.W., Washington, D.C. All Rights Reserved. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

INSTRUCTIONS TO AUTHORS Submit manuscripts in duplicate (original and one (American Chemical Society, 1969). Citations of ab- carbon) to ASM Publications Office, 1913 I St., N.W., stracts, theses, "unpublished data," "personal com- Washington, D.C. 20006. munication," and "in press" will not be accepted in General policy. Any manuscript submitted must be the Literature Cited. a report of unpublished original research, which is not Tables. Each table should be typed on a separate being considered for publication elsewhere. Each page. The data should be arranged so that columns of manuscript should present the results of an independ- like material read down, not across. The headings ent, cohesive study; "series" papers are discouraged. should be sufficiently clear so that the meaning of the A manuscript accepted and published by this journal data will be understandable without reference to the must not be published again in any form without the text. Explanatory footnotes are permitted, but detailed consent of ASM. descriptions of the experiments are not. The materials A charge of $25 per printed page is assessed for and methods used to gain the data should properly publication. Most institutions and granting agencies remain in the section of that name. in the United States permit the payment of publication Figures. A complete set of figures, preferably glossy charges as a part of their general research support. It photographs, should accompany each of the two is recognized, however, that such funds are not always copies of the manuscript. Each figure should be num- available to laboratories outside the United States. bered and should include the name of the author In such cases, the cost of publication will be borne by either in the margin or on the back (marked lightly the American Society for Microbiology. with a soft pencil). Graphs (submit as photographs) The "editorial style" of this journal essentially fol- should be finished drawings not needing further art- lows the Style Manualfor Biological Journals (2nd ed., work or type-setting. Absolutely no part of a graph AIBS, 1964). Genetics symbols should essentially fol- should be typewritten (except the legend, which should low the recommendations of Demerec et al. (Genetics be typed on a separate page). All lettering should be 54:61, 1966) as updated and used by Taylor (Bacteriol. done with a lettering set. Most graphs will be reduced Rev. 34:155, 1970) and Sanderson (Bacteriol. Rev. to one-column width, and all elements in the drawing 34:176, 1970). The standard italicized, lower-case, should be prepared to withstand this reduction. The three-letter symbol should be used for genotype legend of the figure should provide enough informa- lesignation, and care should be taken to avoid using tion so that the figure is understandable without ;his symbol for the designation of phenotype. The reference to the text. Experimental details from Mate- atter can be abbreviated in one form or another, but rials and Methods should not be repeated in figure ;hould be stated in words at first use in the text. legends. 3iochemical abbreviations and nomenclature should Nomenclature of microorganlisms. The name of a ssentially follow "Biochemical Nomenclature" in species is a binary combination consisting of the name r9Iandbook of Biochemistry (2nd ed., 1970. H. A. of the genus followed by a specific epithet. In general, ober, ed. The Chemical Rubber Co., Cleveland, p. the nomenclature presented in Bergey's Manual of k4-A24). Normally, abbreviations (except those of Deterninative Bacteriology (7th ed., 1957) is used. If tandard units of measurement and symbols of the an author challenges this nomenclature, his own judg- lements) should be defined and introduced paren- ment will be followed, but the name in Bergey's hetically at first use in the text. Enzyme activity should Manual should follow in parentheses the first time the )e expressed in terms of international units (Enzyme name is used in the text and in the Abstract. When a Vomenclature, Elsevier Publishing Co., 1965), and the new bacterial name is proposed in a manuscript, an EC number should be given parenthetically at first international authority on nomenclature will be ise in the text. In expressing lengths, weights, and consulted for an opinion. When a new species, or a 'olumes, the prefixes nano (n) and pico (p) should be new variety of a species, is proposed, an acceptable ised instead of millimicro (m,) and micromicro (jAp). photomicrograph or electron micrograph of the cells _xpress lengths in nanometers (nm; 10- m) or in should be submitted. If the cells are motile, the photo- nicrometers (jim; 10-6 m) instead of millimicrons (m,u; micrograph or electron micrograph should show the .09 m), microns (jA: 10-6 m), or Angstroms (A; 10-10 nature and arrangement of flagella. As one of the n). Express parts per million (ppm) as micrograms requirements for description of a new species, we )er milliliter (ug/ml), micrograms per gram (,ug/g), or require deposition of the type culture in a recognized nicroliters per liter (,uliters/liter), as appropriate. In culture collection and designation of the accession ,eneral, measurements should be expressed in terms of number. tandard international metric units. The journal re- Notes. The accepted form for Notes is somewhat erves the privilege of editing manuscripts to make different from the foregoing. Contributors should con- hem conform with the adopted style. sult a recent issue for style. Notes should not exceed Form of manuscript. All parts of the manuscript 500 words. The Abstract should not exceed 25 words. ,hould be typed double-space or, preferably, triple- Copyright. Once a paper has been published in this pace. Most manuscripts can and should be divided journal, which is a copyrighted publication, the legal nto the following sections: Abstract, Introduction, ownership of all parts of the paper, including the illus- wAaterials and Methods, Results, Discussion, Ac- trations, has passed from the author to the ASM. If cnowledgments, and Literature Cited. the same author, or any author, wishes to republish Abstract. An Abstract appears at the beginning of material previously published in this journal, he must ach paper. The Abstract should not exceed 250 words. first receive written permission from ASM. Literature Cited. In the text, references are cited by Reprints. Reprints (in multiples of 100) may be pur- iumber. The Literature Cited section should be typed chased by contributors. A table showing the cost of n alphabetical order, by first author, and numbered. reprints, and an order form, will be sent with the 4ames ofjournals are abbreviated according to Access proof. AUTHOR INDEX

VOLUME 1

Ablashi, D. V., 82 Feeley, John C., 310 Kruse, H., 277 Abramson, I. J., 451 Feingold, David S., 417 Kudo, Kozo, 289 Adamson, R. H., 82 Fiala, Milan, 354 Kunugita, K., 192 Akerkar, A. S., 392 Fitzgerald, Robert J., 296 Kunz, Lawrence J., 30 Aoki, H., 192 Fleck, W., 385 Kushner, D. J., 470 Armstrong, Ellmore, N. W., 82 Fleming, W. A., 1 Asher, Yael, 171, 483 Forland, M. F., 90 Lamb, John W., 323 Fukuda, D. S., 237 Laurell, Gunnar, 422 Ball, Robert J., 80 Lee, I. P., 489 Barza, Michael, 268, 427 Gardner, Mildred, 148 Leech, Irene, 30 Bayne, H. G., 263 Gershon, Herman, 373 Leitner, F., 54, 67 Bear, D., 303 Giron, David J., 78, 80 Levison, Matthew E., 35, 174, Beaty, Harry N., 397 Godfrey, Patricia K., 373 235, 381 Becker, Yechiel, 171, 483 Goldschmidt, Millicent C., 348 Lieberman, Melvin, 143 Bennett, John E., 476 Gordee, Elizabeth Z., 315 Lindstrom, E. Borje, 100 Bergeron, Michel G., 280 Gordon, Ralph C., 504 Lipinski, A. E., 333 Berman, Harris A., 268 Gravelle, M. Joan, 470 Lucas, G. B., 363 Berman, S., 303 Gross, A. J., 367 Lukic, Aruka, 363 Block, Edward R., 476 Guttler, Richard B., 397 Lynch, John E., 185 Bodey, Gerald P., 343, 348, 358 Guze, Lucien B., 354 Borders, D. B., 403 Mabe, J. A., 237, 242, 247- Bradley, S. G., 489 Hahn, Fred E., 259 MacAlister, T. J., 447 Bran, Jose L., 35, 174, 235 Hallander, Hans O., 422 McCall, Charles E., 12 Brannon, D. R., 237, 242, 247 Hanka, L. J., 135 McChatelet, Lawrence R., 12 Brenner, V. C., 116 Hausmann, W. K., 403 McCloskey, R. V., 90 Brusch, John L., 280 Holdeman, Lillian V., 451 McClure, Sheena F., 1 Bryan, L. E., 22 Hplder, William R., 210 McCracken, A. W., 90 Buck, R. E., 67 Holmes, K., 303 Macoregor, R., 303 Burrous, S. E., 85 Huber, F. M., 237 McNeill, T. A., 1, 6 Huppert, M., 367 Mann, Jerry M., 323 Came, Paul E., 143 Hurd, Nancy, 177 Martin, D. G., 135 Carlisle, Harold N., 460 Hurst, A., 277 Martin, William J., 148 Case, C., 263 Medoff, Gerald, 30 Chen, Chi-Pien, 159 lannetta, Antoinette, 466 Mehta, B. M., 470 Cheng, K. -J. Cheng, 447 Ikushima, H., 192 Carmen Chow, Anthony, 354 Imanaka, H., 192 Mercado, M., 73 Ishida, Nakao, 289 Mine, K., 496 Cooper, M. Robert, 12 Minshew, Barbara H., 508 Costerton, J. W., 447 54 Crast, L. B., 54 Jacobs, Richard L., 49 Misiek, M., Jepson, Joanne H., 174 Mitsuhashi, Susumu, 17, 139 Davies, M. C., 403 Jungstand, W., 385 Miyairi, N., 192, 496 Davis, Bernard D., 252 Jurd, L., 263 Miyoshi, T., 192 Davis, Starkey D., 466 Moellering, Robert C., Jr., 30 Day, L. A., 315 Kaye, Donald, 35, 174, 235, 381 Moore, W. E. C., 451 Del Bene, Victor E., 340 Kikuchi, Mikio, 289 Mori, S., 496 Despopoulos, Agamemnon, 112 Killen, M., 1 Morris, A., 283 Dienstag, Jules, 41 King, A. D., Jr., 263 Dixon, J. M. S., 333 Kirby, J. P., 403 Naftchi, N. E., 392 Doyle, Meade A., 310 Kirby, Susan M., 283 Nagarajan, R., 242 Duncan, W. Christopher, 210 Kirby, William M. M., 329, 504 Nance, Jane, 358 Kirchoff, Carol, 412 Neft, N., 274 Ellis, R., 242 Klainer, Albert S., 164 Neu, Harold C., 41, 107 English, Arthur R., 185 Klastersky, Jean, 441 Nordstrom, Kurt, 100 Ennis, Herbert L., 197, 204 Knight, Ralph, 381 Northrup, Robert S., 310 Eudy, W. W., 85 Knox, John M., 210 Kobayashi, Fujio, 17, 139 O'Callaghan, Cynthia H., 283 Farley, T. M., 274 Kohsaka, M., 192 Olenick, John G., 259 Farrar, W. Edmund, 340 Kominek, L. A., 123 Orfanakis, Mike G., 215 * v AUTHOR INDEX ANTIMICROB. AG. CHEMOTHER.

Palmer, Darwin L., 112 Salkin, Ira F., 177 Tomasz, Maria, 73 Parmegiani, Raulo, 373 Saslaw, Samuel, 460 Tseng, Jui Teng, 22 Pascale, Andrea, 143 Schaberg, Dennis, 329 Turck, M., 303 Perkins, Robert L., 164 Schafer, Thomas W., 143 Pindak, Frank F., 78, 80 Schlamm, N. A., 512 Van Den Elzen, H. M., 22 Powers, Kendall G., 49 Schmidt, Jerome P., 78, 80 Vine, Hugh, 427 Prauser, H., 385 Schoenknecht, Fritz, 433 Preston, David A., 221 Schonfeld, C., 385 Warren, Edward, 46 Price, K. E., 54, 67 Seeber, C., 385 Washington, John A. II, 46, 148 Pursiano, T. A., 54 Shadomy, Smith, 412 Watanabe, N., 496 Sherris, J. C., 116 Weinstein, Louis, 268, 427 Rabinovich, Sergio, 408 Shingler, A. H., 283 Welty, R. E., 363 Rael, Eppie D., 112 Simmons, Richard J., 323 Wennersten, Christine, 30 Ray, Verne A., 185 Smith, Charles B., 215 Wetzel, E. R., 403 Regamey, Claude, 329, 504 Snyder, Robert J., 46 Whitney, J. G., 237, 242, 247 Reid, W., 376 Sparling, P. Frederick, 252 Wick, Warren E., 221 Reid, Y., 376 Strauss, D., 385 Wicker, K. J., 247 Reineke, L. M., 135 Sud, Inder Jit, 417 Wiesner, P., 303 Retsema, James A., 185 Sun, S. H., 367 Wilcox, Howard G., 215 Roberts, David P., 210 Sweeney, M. J., 90 Sykes, R. B., 94 Wilkins, T. D., 451 Rose, W. C., 489 Winshell, Elaine B., 107 Rosenblatt, Jon E., 433 Tai, Fu-Hsiang, 159 Rosenblum, E. D., 508 Takano, N., 496 Yamaguchi, Mashito, 17, 139 Tanzer, J. M., 376 Sakai, H., 192 Terry, E. E., 90 Zakay-Rones, Zichriya, 483 SUBJECT INDEX VOLUME 1

Absorbable antibiotics -of actinomycetes, 363 -in fecal flora, 343 Antifungal testing Acid hydrolysis -animal model for, 367 -antibiotic A16886B, 242 Antiplaque agents -glycine from, 242 -preclinical evaluation, 376 Actinomycetes Antipoxvirus antibiotics, 483 -antifungal spectra, 363 Antitumor antibiotic protein Actinomycin production -neocarzinostatin, 289 -by sp., 274 Antiviral agents -factors affecting, 274 -in EAV-infected hamsters, 143 Actinomycin susceptibility Ascorbic acid -of a marine pseudomonad, 447 -effect on hexose monophosphate shunt, 12 Adenine arabinoside Aspergillus niger -effect on growth of H. saimiri, 82 -antifungicide, 373 Amantadine Aspergillus oryzae -comparison with rimantadine, 408 -antifungicide, 373 Amiceten Atmospheric pressure -protein inhibition by, 204 -antibiotic susceptibility, 512 7-Aminocephalosporanic acids -structure-activity relationships, 54 Bacillus megaterium Aminoglycosides -protein biosynthesis, 259 -, 41, 323, 381 Bacitracin susceptibility, 451 Amoxicillin Bacteroides fragilis -comparative pharmacology, 504 -10 antimicrobial agents against, 148 -in vitro, 358 Biguanide chlorhexide -pharmacology, 358 -anticaries agent, 376 Amphotericin B BL-S 217 -5-FC in presence of, 476 -cephalosporanic acid, 67 Ampicillin -properties, 67 -against Nocardia infections, 215 -structure, 67 -combined with sulfonamides, 215 Biotin -comparative pharmacology, 504 -new antimetabolites, 135 Ampicillin susceptibility, 451 Anaerobic C1-C2 aziridine ring -antibiotic susceptibility, 451 -mitomycin compounds lacking, 73 -in vitro antimicrobial susceptibility, 148 Calcium in serum Anaerobic incubation -antagonistic effect, 466 -effect on antibiotic susceptibility, 433 Cancer patients Animal model -chemotherapeutic agents, 348 -for antifungal testing, 367 Carbamate cephalosporin Antagonism of activity -from S. clavuligerus, 237, 247 -of tobramycin, 466 Carbenicillin Antibiotic LL-BL 136, 403 -synergy with tobramycin, 41 Antibiotic-induced alterations Carbenicillin derivative -surface morphology, 164 -orally active, 185 Antibiotic susceptibility Carbenicillin indanyl sodium -elevated atmospheric pressure, 512 -orally active, 185 Antibiotic susceptibility tests Carbenicillin susceptibility, 451 -effect of anaerobic incubation, 433 Cefazolin -reproducibility studies, 116 -new cephalosporin, 221 Antibiotic synergism Cell wall barrier -against listeria, 30 -actinomycin susceptibility, 447 Anticaries agents, 376 Cellular location Antifungal antibiotic -relation to Enterobacter resistance, 107 -cycloheximide, 177 Cephaloridine, 221 -evaluation, 367, 373 Cephalosporanic acids Antifungal spectra -BL-S 217, 67

. . iV SUBJECTr INDEX ANTIMICROB. AG. CHEMOTHER.

-structure-activity relationships, 54 Dehydroascorbic acid Cephalosporin -effect on hexose monophosphate shunt, 12 -cephapirin, 35 Dental caries -new, 303 -antibiotic inhibition of, 296 -S. aureus resistance to, 422 Dental plaques Cephalosporin antibiotics -antibacterial agents, 376 -three new, 221 Detection of ,B-lactamase Cephalosporin C acetyl esterase -with cephalosporin, 283 -formation of g-lactam antibiotic, 237 Diafiltration process Cephalosporin resistance -protein binding of penicillins, 427 -identification, 422 Diaminodiphenyl sulfone, 392 Cephalosporin substrate Dihydro-obtusastyrene -chromogenic, 283 -antimicrobial properties, 263 Cephalosporins Diplococcus pneuwnoniae infection -assay by Autoanalyzer, 100 -effect of interferon inducers, 80 -Enterobacter resistance to, 107 Disc diffusion Cephalothin, 221 -cephalosporin resistance, 422 -protein binding, 427 Distamycin A -susceptibility of anaerobic bacteria, 148 -against poxviruses, 483 Cephalothin susceptibility, 451 Drug resistance Cephanome -in P. aeruginosa, 22 -new cephalosporin, 221 Cephapirin -evaluation, 35, 303 El Tor Cephapirin sodium in serum -susceptibility to sulfamethoxazole, 310 -effect of hemodialysis, 90 -susceptibility to trimethoprim, 310 -effect of renal failure, 90 Elevated atmospheric pressure Cephapirin sodium in urine -effect on susceptibility, 512 -effect of hemodialysis, 90 Endotoxin lethality -effect of renal failure, 90 -with L-asparaginase, 489 Cephapirin therapy -with cyclophosphamide, 489 -neutropenia after, 174 -with daunomycin, 489 Chemoprophylaxis -with methotrexate, 489 -of meningococcal disease, 397 -with pactamycin, 489 Chloramphenicol -with polyinosinic-polycytidylic acid, 489 -susceptibility of anaerobic bacteria, 148 -with procarbazine, 489 Chloramphenicol metabolism -with vincristine, 489 -induction by phenobarbital, 112 Enterobacter resistance Chlorinated lincomycin analogues -relation to 3-lactamase activity, 107 -against falciparum malaria, 49 -relation to cellular location, 107 Chloroquine therapy -to cephalosporins, 107 -for Plasmodium falciparum infections, 49 -to penicillins, 107 Clindamycin Enterotoxin B -in streptococcal infections, 460 -effect on S. aureus, 277 -susceptibility of anaerobic bacteria, 148 Equine abortion virus Clindamycin susceptibility, 451 -antiviral agents, 143 Clinical studies Erythromycin -agents against B. fragilis, 148 -in streptococcal infections, 460 Coccidiomycosis in mice -streptococci resistant to, 333 -for antifungal testing, 367 -susceptibility of anaerobic bacteria, 148 Colony formation Erythromycin resistance -effect of methisazone, 6 -zone phenomenon, 333 Comparative pharmacology Escherichia coli -of two ampicillins, 504 -antibiotic-induced alterations, 164 Congocidine -heterozygotes, 252 -against poxviruses, 483 -polysome metabolism in, 197, 204 Cycloheximide -proflavine binding in, 470 -antifungal properties, 177 -R factor-resistant strains, 139 Cyclophosphamide -resistance to lividomycin, 139 -in cancer treatment, 348 Ethidium bromide -in leukemia treatment, 348 -effect on eukaryotic cells, 171 Cytosine arabinoside Eukaryotic cells -effect on growth of H. saimiri, 82 -ethidium bromide-treated, 171 -in leukemia treatment, 348 Exogenous penicillin -susceptibility of herpesviruses, 354 -penicillin biosynthesis, 315 VOL. 1, 1972 SUBJECr INDEX v

Experimental animal model Hexose monophosphate shunt -for antifungal testing, 367 -effect of ascorbic acid, 12 Human neutrophils Falciparum malaria -hexose monophosphate shunt, 12 -chlorinated lincomycin analogues against, 49 Fecal flora Immune response -resistance of antibiotics, 343 -suppression by methisazone, 1, 6 Feed additive Influenza A infection -thiopeptin, 192, 496 -rimantadine A therapy, 408 5-Fluorocytosine Interferon -pharmacological studies, 476 -effect on D. pneumoniae infection, 80 Fungal diseases -effect on P. tularensis infection, 80 -evaluation of cycloheximide against, 177 Interferon inducers Fungitoxicity -effect in EAV-infected hamsters, 143 -of 8-quinolinols, 373 Interferon induction -by tilorone hydrochloride, 78 -lack of protection, 78 -comparison with tobramycin, 381 -protection against bacteria, 80 -effect of heparin, 329 International Collaborative Study -susceptibility of anaerobic bacteria, 148 -on antibiotic susceptibility testing, 116 Gentamicin/cephalothin -against oxacillin-resistant S. aureus, 441 Kanamycin Gentamicin in serum -susceptibility of anaerobic bacteria, 148 -4-hr assay, 46 Kanamycin resistance Gentamicin/oxacillin -use of tobramycin, 41 -against oxacillin-resistant S. aureus, 441 Gentamicin resistance Labeled precursors -use of tobramycin, 41 -incorporation into A16886B, 247 Gentamicin-resistant Pseudomonas i3-Lactam antibiotics, 237, 242, 247 -susceptibility to tobramycin, 280 ,B-Lactam cephalosporins, 237, 242, 247 Glycine ,3-Lactamase activity -from acid hydrolysis of A16886B, 242 -microiodometric determination, 94 Gonorrhea -relation to Enterobacter resistance, 107 -treatment with , 210 ,B-Lactamases Gram-negative bacterium -detection, 283 -actinomycin susceptibility, 447 Lincomycin -streptococci resistant to, 333 Hamsters -susceptibility of anaerobic bacteria, 148 -equine abortion virus-infected, 143 Lincomycin analogues Hemodialysis -against falciparum malaria, 49 -clearance of cephapirin from blood, 90 Lincomycin resistance Hemopoietic cellular response -zone phenomenon, 333 -suppression by methisazone, 1 Listeria monocytogenes Hemopoietic colony formation -antibiotic synergism against, 30 -effect of methisazone in vitro, 6 Lividomycin Heparin -against P. aeruginosa, 17 -inhibition of gentamicin, 329 -enzymatic inactivation, 17 Hepatic clearance -inactivation, 17, 139 -by phenobarbital, 112 -R factor-resistant E. coli, 139 Herpes simplex type 2 -resistance to cytosine arabinoside, 354 "Mandelic-tetrazole" derivative Herpesvirus -"CMT," 221 -susceptibility to cytosine arabinoside, 354 Meningococcal disease Herpesvirus group -minocycline chemoprophylaxis, 397 -antiviral agents, 143 6-Mercaptopurine Herpesvirus saimiri -in cancer treatment, 348 -effect of adenine arabinoside, 82 Methicillin -effect of cytosine arabinoside, 82 -in streptococcal infections, 460 -effect of rifamycin SV, 82 -staphylococci resistant to, 235 -effect of tilorone, 82 Methisazone -multiplication in vitro, 82 -suppression of hemopoietic cellular response, 1, 6 3-Heterocyclic-thiomethyl antibiotics -suppression of immune response, 1 -biological properties, 221 Methotrexate Heterozygotes -use in cancer patients, 348 -spectinomycin in, 252 a-Methylbiotin Vi SUBJECT INDEX ANTIMICROB. AG. CHEMOTHER.

-metabolite of biotin, 135 Penicillin biosynthesis a-Methyldethiobiotin -exogenous penicillin, 315 -metabolite of biotin, 135 Penicillin fermentation Microiodometric method -effect of phenoxymethylpenicillin, 315 -adapted for penicillin, 100 Penicillin G -for ,B-lactamase assay, 94 -for gonorrhea treatment, 210 Minocycline -susceptibility of anaerobic bacteria, 148 -for meningococcal disease, 397 Penicillin susceptibility, 451 Mitomycin C Penicillinases -chemical derivatives, 73 -assay by Autoanalyzer, 100 Mitomycin-related compounds Penicillins -lacking C1-C2 aziridine ring, 73 --assay by Autoanalyzer, 100 MM virus infection -Enterobacter resistance to, 107 -lack of protection by interferon, 78 Permeability barriers Monkeys -relation to proflavine binding, 470 -streptococcal infections in, 460 Periodontal disease Morphological alterations -agents against, 376 -antibiotic-induced, 164 Phenobarbital Mycobacterium tuberculosis -induction of chloramphenicol metabolism by, 112 -inhibition of growth, 392 Phenoxymethylpenicillin Myrothecium verrucaria -effect on penicillin fermentation, 315 -antifungicide, 373 Plasmodium Jalciparum infections -chloroquine therapy, 49 Nafacillin Polymorphonuclear leukocytes -protein binding, 427 -hexose monophosphate shunt, 12 Natural phenols Polymyxin B -antimicrobial properties, 263 -P. mirabilis resistance to, 417 Nebramycin factor 6 Polysome metabolism -tobramycin, 41, 323, 412 -effect of amicetin on, 204 Neisseria meningitidis -in E. coli, 197, 204 -minocycline activity against, 397 -in vivo, 197, 204 Neocarzinostatin Polysome stability -biogenesis, 289 -antibiotic effect on, 197, 204 Neutropenia Poxvirus -after cephapirin therapy, 174 -antibiotics against, 483 Neutrophils Primaquine -hexose monophosphate shunt, 12 -mode of action, 259 Nisin Proflavine binding -effect on S. lactis, 277 -in E. coli, 470 Nocardia asteroides -relation to permeability, 470 -antibiotic therapy against, 215 Protected environment Nonabsorbable antibiotics -oral antibiotic prophylaxis in, 343 -in fecal flora, 343 Protein binding of penicillins Novobiocin -reversibility, 427 -biosynthesis by S. niveus, 123 Protein biosynthesis Novobiocin synthesis -in B. megaterium, 259 -proposed pathway, 123 -inhibition by primaquine, 259 Protein synthesis Obligate parasitism -antibiotic-induced alterations in, 164 -of trachoma agent, 171 -inhibition by amicetin, 204 Obtusastyrene -inhibition by antibiotics, 197, 204 -antimicrobial properties, 263 Proteus mirabilis Oral prophylaxis -resistance to polymyxin B, 417 -in protected environment, 343 Proteus species Owl monkeys -carbenicillin against, 185 -falciparum malaria in, 49 Pseudomonas Oxacillin -gentamicin-resistant, 280 -protein binding, 427 -in leukemic patients, 348 Oxacillin-resistant staphylococci -tobramycin against, 466 -antibiotic susceptibility of, 441 Pseudomonas aeruginosa -antibiotic-induced alterations, 164 Pasteurella tularensis infection -carbenicillin against, 185 -effect of exogenous L-cell interferon, 80 -lividomycin against, 17 -effect of interferon inducers, 80 -toxicity of vincristine with, 489 VOL. 1, 1972 SUBJECT INDEX *ii

-transferable drug resistance, 22 Streptococcus mutans Pyelonephritis -from carious rats, 296 -P. mirabilis-induced, 85 Streptococcus pyogenles Pyocin B39 -antibiotic susceptibility, 512 -chemical properties, 159 -resistance to erythromycin, 333 -physical properties, 159 -resistance to lincomycin, 333 -purification, 159 Streptomyces antibioticus -growth in chemically defined medium, 274 8-Quinolinols Streptomyces carzinostatin -antifungal activity, 373 -neocarzinostatin from, 289 Quinolyl aryl ethers Streptomyces clavuligerus -antimicrobial activity, 392 -cephalosporin from, 237, 242, 247 Quinolyl aryl sulfides Streptomyces diastatochromogenes -antimicrobial activity, 392 -trypanomycin from, 385 Quinolyl aryl sulfones Streptomyces niveus -antimicrobial activity, 392 -biosynthesis of novobiocin by, 123 Streptomyces species R factor-resistant Escherichia coli -actinomycin production by, 274 -activity of lividomycin, 139 Streptomyces spectabilis Renal lysozyme -antibiotic from, 210 -elevation after P. mirabilis infection, 85 Streptomyces iateyamensis -elevation by ampicillin, 85 -thiopeptin from, 192, 496 -elevation by kanamycin sulfate, 85 Streptomyces tenebrarius -elevation by nitrofurantoin, 85 -tobramycin from, 41 Reproducibility of antibiotic susceptibility tests Streptomycin -with different media, 116 -bactericidal action, 252 Resistance to drugs -comparison with spectinomycin, 252 -in P. aeruginosa, 22 Streptothricin-type antibiotics Rifampin -analytical method, 403 -susceptibility of anaerobic bacteria, 148 Structure-activity relationships Rifamycin SV -among cephalosporanic acids, 54 -effect on growth of H. saimiri, 82 Sulfamethoxazole Rimantadine -susceptibility of V. cholerae, 310 -for influenza A therapy, 408 Sulfonamide -concentration in serum, 268 Salmonella typhosa endotoxin -oral administration, 268 -toxicity for mice, 489 Sulfonamide concentration Semisynthetic penicillin -chemical determination, 268 -amoxicillin, 358 Sulfonamides Serum sulfonamide concentration -against Nocardia infections, 215 -two bioassay techniques, 268 -combined with ampicillin, 215 Sheep erythrocytes Susceptibility testing -suppressive activity of methisazone, 1 -of anaerobic bacteria, 451 Spectinomycin Synergistic action -comparison with streptomycin, 252 -against L. monocytogenes, 30 Spectinomycin hydrochloride -for gonorrhea treatment, 210 Technicon Autoanalyzer system Staphylococci -for penicillin assay, 100 -methicillin-resistant, 235 Tetracycline Staphylococcus aureus -susceptibility of anaerobic bacteria, 148 -antibiotic-induced alterations, 164 Tetracycline resistance -antibiotic susceptibility, 512 -in S. epidermidis, 508 -cephasporin-resistant strains, 422 -transduction of, 508 -effect of enterotoxin B, 277 Tetracycline susceptibility, 451 -methicillin-resistant strains, 235 Thiopeptin -oxacillin-resistant strains, 441 -chemical studies, 192 Staphylococcus epidermidis -feed additive, 192 -tetracycline resistance in, 508 -microbiological studies, 192 Streptococcal infections -new feed additive, 496 -in monkeys, 460 Thiopeptin A antibiotics Streptococci -comparison with thiopeptin B, 192 -group A beta-hemolytic, 333 Tilorone Streptococcus lactis -effect on growth of H. saimiri, 82 -inhibition by nisin, 277 Tilorone hydrochloride viii SUBJECT INDEX ANTIMICROB. AG. CHEMOTHER.

-induction of interferon by, 78 Trichophyton mentagrophytes Tobacco -antifungicide, 373 -actinomycetes from, 363 Trimethoprim Tobramycin -susceptibility of V. cholerae, 310 -against Pseudomonas, 466 Trypanomycin -evaluation, 412 -characterization, 385 -in vitro evaluation, 381 -fermentation, 385 -in vitro studies, 41, 412 -isolation, 385 -microbiological assay, 323 -screening, 385 -susceptibility of Pseudomonas, 280 -synergy with carbenicillin, 41 Urinary tract antibiotics Tobramycin activity levels, 85 -effect of calcium in serum, 466 -effect on renal lysozyme Tobramycin assay -agar-plate, 323 Venereal disease -iron and sodium ions, 323 -spectinomycin hydrochloride, 210 Toxicity of vincristine Vibrio cholerae, classical strains -with P. aeruginosa, 489 -susceptibility to sulfamethoxazole, 310 -with S. typhosa endotoxin, 489 -susceptibility to trimethoprim, 310 Trachoma agent Vincristine -obligate parasitism, 171 -enhanced toxicity, 489 Trichoderma viride Virus inhibitory titers -antifungicide, 373 -method to measure, 354